Technical Analysis for CLLS - Cellectis S.A.

Grade Last Price % Change Price Change
F 1.80 1.12% 0.02
CLLS closed up 1.12 percent on Friday, November 1, 2024, on 2.5 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 4
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish 1.12%
New 52 Week Closing Low Bearish 1.12%
Stochastic Reached Oversold Weakness 1.12%
Inside Day Range Contraction 1.12%
Gapped Up Strength 1.12%
Down 3 Days in a Row Weakness 1.12%
Oversold Stochastic Weakness 1.12%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 17 hours ago
2x Volume Pace about 19 hours ago
1.5x Volume Pace about 19 hours ago
3x Volume Pace about 19 hours ago
Up 1% about 19 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cellectis S.A. Description

Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Solid Tumors Acute Myeloid Leukemia Leukemia Blastoma Multiple Myeloma Glioblastoma Hematologic Malignancies Oncogenes Genome Chimeric Antigen Receptor Chronic Lymphocytic Leukemia Lymphocytic Leukemia Adoptive Cell Transfer Tumors Of The Hematopoietic And Lymphoid Tissues CD19 Cell Product Acute Lymphoblastic Leukemia Cellectis

Is CLLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.7735
52 Week Low 1.77
Average Volume 34,919
200-Day Moving Average 2.42
50-Day Moving Average 2.11
20-Day Moving Average 1.90
10-Day Moving Average 1.85
Average True Range 0.11
RSI (14) 39.02
ADX 27.45
+DI 8.95
-DI 20.08
Chandelier Exit (Long, 3 ATRs) 1.75
Chandelier Exit (Short, 3 ATRs) 2.10
Upper Bollinger Bands 2.03
Lower Bollinger Band 1.76
Percent B (%b) 0.14
BandWidth 14.37
MACD Line -0.08
MACD Signal Line -0.08
MACD Histogram -0.0005
Fundamentals Value
Market Cap 128.85 Million
Num Shares 71.6 Million
EPS -1.41
Price-to-Earnings (P/E) Ratio -1.28
Price-to-Sales 8.90
Price-to-Book 2.88
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.85
Resistance 3 (R3) 1.85 1.83 1.84
Resistance 2 (R2) 1.83 1.82 1.83 1.84
Resistance 1 (R1) 1.82 1.81 1.82 1.82 1.84
Pivot Point 1.80 1.80 1.80 1.80 1.80
Support 1 (S1) 1.78 1.78 1.78 1.78 1.76
Support 2 (S2) 1.76 1.77 1.76 1.76
Support 3 (S3) 1.75 1.76 1.76
Support 4 (S4) 1.75